Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing

    NEXT STORY
    WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications
    PREV STORY
    AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Twin Cities Med-Tech Company Provation Creates Free Coronavirus Resource for All Healthcare Professionals

    author_avatar
    NASDAQ Market News

    Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million

    author_avatar
    NASDAQ Market News

    RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®

    author_avatar
    NASDAQ Market News